HERMES: Randomised trial of 2-fraction or 5-fraction MRI-guided adaptive prostate radiotherapy
To demonstrate safety and feasibility of 2-fraction stereotactic body radiotherapy (SBRT) for prostate cancer.
Related Articles
Updates from 2024 Survivor Circle Grants Awardees – ASTROblog – American Society for Radiation Oncology (ASTRO)
At the 66th Annual Meeting last fall in Washington, DC, two organizations based in the Washington, DC-Maryland-Virginia (DMV) region, Smith Center for Healing and the…
CUMULATIVE RISK OF COSMETIC WORSENING FOLLOWING ULTRA HYPO-FRACTIONATED WHOLE BREAST RADIOTHERAPY WITH SIMULTANEOUS INTEGRATED BOOST: THE LARGEST REAL-WORLD DATA
Randomised trials have shown that ultra-hypofractionated radiotherapy [uHFRT] is a safe alternative for breast radiotherapy [RT]. However, its safety in patients requiring tumour bed boost…
The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated With Adjuvant Radiation Therapy: A Multi-Institutional Retrospective Study
To assess the impact of MLH1 promoter hypermethylation (MLH1ph) on prognosis and define the patterns of recurrence in stage I or II endometroid endometrial cancer…
Elections – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
ASTRO holds annual elections for its Board of Directors.
Dosimetric Comparison of MRI-Guided Versus Reduced Margin CT-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Post-Hoc Analysis of a Phase III Trial
The MIRAGE trial (NCT04384770) showed that aggressive planning target volume (PTV) margin reduction, achieved by leveraging the advanced image-guidance of MRI-guided (MRg) radiotherapy, led to…
Minority Summer Fellowship Awardees – American Society for Radiation Oncology (ASTRO)
View a list of past and present Minority Summer Fellowship awardees.
Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study
Pembrolizumab is approved for PD-L1+ but not PD-L1 negative metastatic, recurrent, or persistent cervical cancer. Response rates to single agent anti-PD-1/PD-L1 therapy have been modest…
Stereotactic Reirradiation: Final Results From a Phase 1 Dose Escalation Trial (DESTROY-1)
The final results of the Dose Escalation STereotactic RadiOtherapY-1 (DESTROY-1) trial arms focusing on stereotactic radiation therapy (SBRT) retreatment of recurrences occurring >4 months after…
Medical Student Q&A – Medical Students – American Society for Radiation Oncology (ASTRO)
Join us for our bi-monthly Medical Student Q&A where you will have the opportunity to meet faculty and resident radiation oncologists.
Unlocking the Radiosensitizing Potential of MYC Inhibition in Neuroendocrine Malignancies
The MYC family of transcription factors—comprising c-MYC, N-MYC, and L-MYC—plays a pivotal role in oncogenesis, driving cancer progression and resistance to therapy. While MYC proteins…